Richardpruen (talk | contribs) (Dermatitis study added) |
Richardpruen (talk | contribs) (→2014 Role for the nicotinic cholinergic system in movement disorders; therapeutic implications: Added human study on oral tobacco Snus/Snuff) |
||
| Line 965: | Line 965: | ||
<br> | <br> | ||
='''Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals'''= <!--T:186--> | ='''Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals'''= | ||
=== 2023: [https://www.medscape.com/viewarticle/995075?form=fpf Oral Tobacco Use Linked to Slower MS Progression] === | |||
* Jing Wu, Tomas Olsson, Jan Hillert, Lars Alfredsson, Anna Karin Hedström | |||
* Corresponding author Jing Wu, Karolinska Institute, 171 77 Stockholm, Stockholm, Sweden; Email: jing.wu [at] ki.se [Please demangle the email address; spam prevention ed.] | |||
* [https://jnnp.bmj.com/content/94/8/589 Full Text] | |||
* Oral tobacco use, also known as moist snuff, is associated with slower progression of multiple sclerosis (MS), a new study shows. | |||
* Jing Wu, PhD candidate "Our finding that snuff use is not associated with worse disease progression indicates that nicotine replacement therapy could be an attractive way to increase the chance of quitting smoking post diagnosis," | |||
* To investigate, the researchers analyzed data from 9089 patients with MS who were participants in two case-control studies from the Swedish MS registry, mean age 37.6 years and 72% female. At baseline, current cigarette smokers had significantly higher Expanded Disability Status Scale (EDSS) scores compared with nonsmokers. | |||
* All analyses controlled for age at diagnosis, sex, disease phenotype, disease duration, baseline EDSS, and use of disease-modifying therapy. | |||
* Compared with never smoking, current smoking was associated with an increased risk of clinical disease worsening (CDW) (adjusted hazard ratio [aHR] 1.13; 95% CI 1.06-1.21), of reaching EDSS 3 (aHR 1.21, 95% CI 1.09-1.34), and EDSS 4 (aHR 1.31, 95% CI 1.14-1.51). In addition, compared with never smokers, current smoking was associated with a higher risk of physical and psychological worsening as determined by the MS Impact Scale-29 (MSIS-29), and worsening cognitive performance measured by the Symbol Digit Modalities Test (SDMT). | |||
* The study revealed a dose-dependent relationship between smoking and negative MS-related outcomes. | |||
* Current snuff use was significantly associated with lower risk of reaching EDSS 4 (aHR 0.73, 95% CI 0.58-0.92), but not CDW or EDSS 3. It was not significantly associated with the risk of worsening health-related quality of life or cognition. | |||
* In a perplexing turn of events study co-author Anna Karin Hedström, MD, PhD said "Physicians should not recommend smoking MS patients switch to snuff, as snuff may have other negative health consequences." [Why not? if the alternative is continued smoking? ed.] Particularly considering she also said this "This indicates that nicotine is not the substance that leads to worse prognosis and that nicotine replacement therapy is probably harmless — at least with respect to disease progression."<!--T:186--> | |||
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== <!--T:187--> | ===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== <!--T:187--> | ||
edits